An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new discussion in the cancer community is comparing two very different types of treatments — low-dose aspirin and a class of drugs called GLP-1 receptor agonists (GLP-1RAs) — for whether they might help prevent colorectal cancer (cancer of the colon or rectum). The conversation is not about a single decisive study. Instead, experts are weighing existing evidence, some old and some new, to ask whether either approach could lower cancer risk and whether it's worth recommending more widely. Aspirin is an old, cheap pill many people take for pain or to prevent heart attacks. Over decades researchers have noticed that people taking daily low-dose aspirin seem to have a slightly lower risk of developing colorectal cancer. GLP-1 receptor agonists are newer drugs used mainly for diabetes and, more recently, for weight loss (you’ve probably heard brand names like Ozempic or Wegovy). These drugs mimic a natural hormone that helps control blood sugar and appetite. They work in different ways, so the idea that either could affect cancer risk comes from different types of studies and clues. The evidence for aspirin reducing colorectal cancer risk is the strongest of the two, but it’s not simple. Multiple large studies and long-term follow-ups suggest a modest protective effect, especially with many years of use. However, the benefit is gradual and appears after long-term use, and the size of the effect can vary across studies. For GLP-1RAs, the data are much more preliminary. Some laboratory studies and early human observations hint that these drugs might influence processes linked to cancer growth, potentially through effects on weight, metabolism, or inflammation. But randomized trials specifically designed to test colorectal cancer prevention with GLP-1RAs are lacking. In short: aspirin has more population-level data; GLP-1RA ideas are intriguing but not proven for this use. Why this matters is practical. Colorectal cancer is common and often preventable or caught early with screening. If a cheap drug like aspirin truly cuts risk, it could be a useful public-health tool for some people. If GLP-1RAs also reduce cancer risk, that would be important because those drugs are already being used widely for diabetes and weight loss. People deciding about long-term aspirin use, or considering GLP-1RA treatment for other reasons, would want to know whether there’s an added cancer benefit. Clinicians and health agencies need good evidence to recommend any drug for prevention, because prevention often means healthy people would take medicine for years. There are important caveats and risks. Aspirin can cause bleeding, including serious stomach or brain bleeds, and its benefits for cancer prevention must be balanced against that risk. GLP-1RAs carry side effects like nausea and may have other long-term unknowns; they are also much more expensive. Crucially, the strongest evidence linking aspirin to reduced colorectal cancer comes from long-term use, and for GLP-1RAs the evidence is not yet strong enough to justify taking them specifically to prevent cancer. Neither approach replaces standard screening like colonoscopy. Regulatory agencies have not approved GLP-1RAs for cancer prevention, and any decision about starting aspirin for this purpose should be made with a doctor. Bottom line: aspirin has some evidence for modest colorectal cancer prevention but comes with bleeding risks; GLP-1 receptor agonists are an interesting possibility but lack solid proof for preventing colorectal cancer at this time.
Source: The ASCO Post